NCT06989788View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, in Healthy Adults

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 6, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Chronic Hepatitis b
Interventions
BIOLOGICAL

AVX70371

AstriVax Therapeutics' HBV immunotherapeutic

OTHER

Placebo

Placebo

Trial Locations (1)

Unknown

University Hospital Ghent - Centrum voor Vaccinologie (CEVAC), Ghent

Sponsors
All Listed Sponsors
lead

AstriVax Therapeutics

INDUSTRY